Carcinoma of Unknown Primary — Trials

Carcinoma of Unknown Primary — Trials · CancerIndex

Clinical trials

Registered studies

14,235 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,156
Recruiting: 2,259
Ph III recruiting: 267
Growth YoY: +12.6%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,895)

clinicaltrialsPublishedShowing 601–650 of 2,261 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03641313	Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer	active not recruiting	Phase 2	17	National Cancer Institute (NCI)NIH	1	Jul 30, 2026	clinicaltrials
NCT04657068	A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors	recruiting	Phase 1 / Phase 2	542	Artios Pharma LtdINDUSTRY	4	Jul 30, 2026	clinicaltrials